MDEA: Difference between revisions

Line 3:

'''3,4-Methylenedioxy-N-ethylamphetamine''' (also known as~~, '''Methylenedioxyethylamphetamine''',~~ '''MDEA''', '''MDE''', and colloquially as '''Eve''') is ~~an obscure, synthetic~~ [[Psychoactive class::entactogen]] of the [[Chemical class::~~amphetamines|substituted~~ amphetamine]] class ~~that produces modified [[MDMA|MDMA-like]] entactogenic effects when [[routes of administration|administered]]~~. It is ~~a closely related structural analog of~~ [[MDMA]] and [[MDA]]<ref name="Isomer Design">{{cite web|title=Read #22 2C-C {{!}} PiHKAL · info|url=http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=22|website=isomerdesign.com|language=en}}</ref> ~~that acts via the same pharmacological mechanism as a~~ [[serotonin]], [[norepinephrine]], and [[dopamine]] ~~[[releasing agent]] and [[reuptake inhibitor]]~~.<ref name="MDEApharm">Freudenmann RW, Spitzer M (2004). "The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)". CNS Drug Reviews. 10 (2): 89–116. https://doi.org10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.</ref>

'''3,4-Methylenedioxy-N-ethylamphetamine''' (also known as '''MDEA''', '''MDE''', and colloquially as '''Eve''') is a lesser-known [[Psychoactive class::entactogen]] substance of the [[Chemical class::amphetamine]] class. MDEA is chemically similar to [[MDMA]] and [[MDA]].<ref name="Isomer Design">{{cite web|title=Read #22 2C-C {{!}} PiHKAL · info|url=http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=22|website=isomerdesign.com|language=en}}</ref> It produces its effects by increasing levels of [[serotonin]], [[norepinephrine]], and [[dopamine]] in the brain.<ref name="MDEApharm">Freudenmann RW, Spitzer M (2004). "The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)". CNS Drug Reviews. 10 (2): 89–116. https://doi.org10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.</ref>

The first recorded human use of MDEA was in 1976 by [[Alexander Shulgin]], who noted its similarity to [[MDMA]] in both effects and potency, though faster to act and shorter in duration.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #2". Lafayette, CA. (1976-1980). p206 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook2_searchable.pdf</ref>. The synthesis and pharmacological evaluation of MDEA and a series of related compounds were published in 1980.<ref>Braun U, Shulgin AT, Braun G. "Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)." J Pharm Sci. 1980 Feb;69(2):192-5. | https://www.ncbi.nlm.nih.gov/pubmed/6102141</ref>. MDEA is included in Shulgin's 1991 book "[[PiHKAL]]" ("[[Phenethylamine]]s I Have Known and Loved").<ref name="Isomer Design" />

The first recorded human use of MDEA was in 1976 by [[Alexander Shulgin]], who noted its similarity to [[MDMA]] in both effects and potency, though faster to act and shorter in duration.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #2". Lafayette, CA. (1976-1980). p206 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook2_searchable.pdf</ref> The synthesis and pharmacological evaluation of MDEA and a series of related compounds were published in 1980.<ref>Braun U, Shulgin AT, Braun G. "Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)." J Pharm Sci. 1980 Feb;69(2):192-5. | https://www.ncbi.nlm.nih.gov/pubmed/6102141</ref> MDEA is included in Shulgin's 1991 book "[[PiHKAL]]" ("[[Phenethylamine]]s I Have Known and Loved").<ref name="Isomer Design" />

In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance two years later.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref> Since then, MDEA has rarely been sold on its own and has largely been used as an occasional additive or substitute ingredient in pills of "Ecstasy".<ref name="MDEApharm" />

While MDEA shares many of the core entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up only in small batches synthesized and distributed by hobbyist clandestine chemists.{{citation needed}}

Very little data exists about the pharmacological properties, metabolism, and toxicity of MDEA,. As a result it is highly advised to approach this potentially habit-forming [[entactogenic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it.

Very little data exists about the pharmacological properties, metabolism, and toxicity of MDEA, ~~and it has little history of human usage~~. As a result it is highly advised to approach this potentially habit-forming [[entactogenic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it.

==History and culture==

@@ Line 3: / Line 3: @@
 {{SubstanceBox/MDEA}}
-'''3,4-Methylenedioxy-N-ethylamphetamine''' (also known as, '''Methylenedioxyethylamphetamine''', '''MDEA''', '''MDE''', and colloquially as '''Eve''') is an obscure, synthetic [[Psychoactive class::entactogen]] of the [[Chemical class::amphetamines|substituted amphetamine]] class that produces modified [[MDMA|MDMA-like]] entactogenic effects when [[routes of administration|administered]]. It is a closely related structural analog of [[MDMA]] and [[MDA]]<ref name="Isomer Design">{{cite web|title=Read #22 2C-C {{!}} PiHKAL · info|url=http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=22|website=isomerdesign.com|language=en}}</ref> that acts via the same pharmacological mechanism as a [[serotonin]], [[norepinephrine]], and [[dopamine]] [[releasing agent]] and [[reuptake inhibitor]].<ref name="MDEApharm">Freudenmann RW, Spitzer M (2004). "The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)". CNS Drug Reviews. 10 (2): 89–116. https://doi.org10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.</ref>
+'''3,4-Methylenedioxy-N-ethylamphetamine''' (also known as '''MDEA''', '''MDE''', and colloquially as '''Eve''') is a lesser-known [[Psychoactive class::entactogen]] substance of the [[Chemical class::amphetamine]] class. MDEA is chemically similar to [[MDMA]] and [[MDA]].<ref name="Isomer Design">{{cite web|title=Read #22 2C-C {{!}} PiHKAL · info|url=http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=22|website=isomerdesign.com|language=en}}</ref> It produces its effects by increasing levels of [[serotonin]], [[norepinephrine]], and [[dopamine]] in the brain.<ref name="MDEApharm">Freudenmann RW, Spitzer M (2004). "The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA)". CNS Drug Reviews. 10 (2): 89–116. https://doi.org10.1111/j.1527-3458.2004.tb00007.x. PMID 15179441.</ref>
-The first recorded human use of MDEA was in 1976 by [[Alexander Shulgin]], who noted its similarity to [[MDMA]] in both effects and potency, though faster to act and shorter in duration.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #2". Lafayette, CA. (1976-1980). p206 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook2_searchable.pdf</ref>. The synthesis and pharmacological evaluation of MDEA and a series of related compounds were published in 1980.<ref>Braun U, Shulgin AT, Braun G. "Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)." J Pharm Sci. 1980 Feb;69(2):192-5. | https://www.ncbi.nlm.nih.gov/pubmed/6102141</ref>. MDEA is included in Shulgin's 1991 book "[[PiHKAL]]" ("[[Phenethylamine]]s I Have Known and Loved").<ref name="Isomer Design" />
+The first recorded human use of MDEA was in 1976 by [[Alexander Shulgin]], who noted its similarity to [[MDMA]] in both effects and potency, though faster to act and shorter in duration.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #2". Lafayette, CA. (1976-1980). p206 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook2_searchable.pdf</ref> The synthesis and pharmacological evaluation of MDEA and a series of related compounds were published in 1980.<ref>Braun U, Shulgin AT, Braun G. "Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)." J Pharm Sci. 1980 Feb;69(2):192-5. | https://www.ncbi.nlm.nih.gov/pubmed/6102141</ref> MDEA is included in Shulgin's 1991 book "[[PiHKAL]]" ("[[Phenethylamine]]s I Have Known and Loved").<ref name="Isomer Design" />
 In the United States, MDEA was introduced recreationally in 1985 as a legal substitute to the newly banned MDMA before it was made a Schedule I substance two years later.<ref>PiHKAL|http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=106</ref> Since then, MDEA has rarely been sold on its own and has largely been used as an occasional additive or substitute ingredient in pills of "Ecstasy".<ref name="MDEApharm" />
-While MDEA shares many of the core entactogenic properties of MDMA, it is slightly less potent and considered to be more "stoning", lacking the pro-socializing and energizing "magic" most party-goers seek in their MDMA experiences. As a result, it is largely considered by most people to be a less desirable variant of MDMA and is thus rarely produced and sold in the illicit drug market, typically showing up only in small batches synthesized and distributed by hobbyist clandestine chemists.{{citation needed}}
+Very little data exists about the pharmacological properties, metabolism, and toxicity of MDEA,. As a result it is highly advised to approach this potentially habit-forming [[entactogenic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it.
-Very little data exists about the pharmacological properties, metabolism, and toxicity of MDEA, and it has little history of human usage. As a result it is highly advised to approach this potentially habit-forming [[entactogenic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it.
 ==History and culture==